A Study of Eosinophil Activities in Healthy Subjects and Subjects with Allergic/immunologic Disorders

Overview

  • Study type

    Observational
  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Scottsdale/Phoenix, Arizona: 17-007025
    Sponsor Protocol Number: 17-007025

About this study

The purpose of this study is to investigate eosinophil activities and interactions with other cell types in vitro to better understand how they contribute to health and disease.  Specifically, we will isolate eosinophils and other white blood cells from peripheral blood and subject them to various stimuli as well as co-culture conditions to examine activities and interactions. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria:

  • The normal controls are healthy individuals with no history of eosinophil-associated diseases. 
  • Subjects are healthy individuals except for eosinophil-associated disease conditions as described here. 
  • Patients with asthma are selected based on a diagnosis that includes their histories of recurrent wheezing and chest tightness and an asthma diagnosis from current or previous physicians. 
  • Patients with eosinophilic esophagitis are selected based on diagnosis of EoE from current or previous physicians.

Exclusion Criteria: 

  • Patients who have received systemic glucocorticoids or high-dose (>1,000 µg/day) inhaled glucocorticoids during the past 3 months or who are previous or current smokers will be excluded.
  • Patients who have received oral or swallowed steroids within the past 6 weeks will be excluded.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Benjamin Wright

Open for enrollment

Contact information:

Benjamin Wright

(480)301-4284

Wright.Benjamin@mayo.edu

.
CLS-20357369

Mayo Clinic Footer